Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable lung condition defined by persistent airflow limitation that is not fully reversible and usually progresses over time. It is the endpoint of decades of damage — most often from cigarette smoke — that thickens and narrows the airways and destroys the delicate elastic tissue of the lungs. What makes COPD so important to understand is its scale and its tragedy: it is one of the leading causes of death worldwide, almost entirely driven by an exposure we know how to remove, yet millions live breathless because it is diagnosed late.

This page teaches COPD the way a good pulmonologist thinks about it — from the pathology of the airways and air sacs, through the physiology of trapped air and the mechanics of a flattened diaphragm, to the practical business of confirming the diagnosis with spirometry and choosing therapies that actually change how a patient feels and how long they live.

Learning Objectives

• Define COPD and distinguish chronic bronchitis from emphysema at the pathological and clinical level.
• Explain how cigarette smoke and other exposures cause fixed airflow limitation and gas trapping.
• Interpret post-bronchodilator spirometry and apply GOLD staging and the ABE assessment.
• Recognise, grade, and manage an acute exacerbation of COPD.
• Build a stepwise management plan spanning smoking cessation, inhalers, pulmonary rehabilitation, oxygen, and end-of-life care.
• Avoid the common diagnostic and prescribing errors that lead to poor outcomes.

Quick Answer

COPD is chronic, largely irreversible airflow limitation caused mainly by smoking and characterised by two overlapping processes: chronic bronchitis (airway inflammation with cough and sputum) and emphysema (destruction of alveolar walls, loss of elastic recoil, and gas trapping). Patients present with progressive breathlessness, chronic productive cough, and reduced exercise tolerance. Diagnosis requires spirometry showing a post-bronchodilator FEV1/FVC ratio below 0.70. Management rests on smoking cessation and vaccination, inhaled bronchodilators (LABA and LAMA) with inhaled corticosteroids for selected patients, pulmonary rehabilitation, and long-term oxygen for chronic hypoxaemia. Exacerbations are treated with increased bronchodilators, steroids, antibiotics when indicated, and controlled oxygen.

Where It Came From

For most of medical history, the chronic breathlessness and "smoker's cough" of older men were regarded as an unavoidable part of ageing or a moral failing of constitution. Emphysema was described anatomically as early as the 18th century — René Laënnec, who invented the stethoscope in 1816, wrote vivid descriptions of overinflated, air-filled lungs at autopsy — but no one connected these findings to a preventable cause. The pieces were there; the motivation to assemble them was not, because tobacco was culturally beloved and its harms invisible on any short timescale.

The turning point came in the mid-20th century, when lung cancer and chronic bronchitis were rising with alarming speed in industrialised nations. The pressing question was: why? In 1950 Richard Doll and Austin Bradford Hill published a landmark case-control study in the British Medical Journal showing a powerful link between smoking and lung cancer, followed by their British Doctors Study, which prospectively tracked tens of thousands of physicians and demonstrated dose-dependent harm from tobacco — including to the airways, not just cancer risk. Charles Fletcher's classic longitudinal work in the 1970s (the "Fletcher-Peto curve") then showed exactly how smoking accelerates the normal age-related decline in FEV1, and — crucially — that stopping smoking flattens that decline back toward a normal slope. This was the motivating insight that transformed COPD from a fatalistic diagnosis into a modifiable disease: the damage already done cannot be undone, but the trajectory can be changed. The 1964 US Surgeon General's Report cemented smoking as a public-health emergency, and the later GOLD (Global Initiative for Chronic Obstructive Lung Disease) framework, launched around 2001, gave clinicians worldwide a shared language for staging and treatment.

The Two Faces of COPD: Chronic Bronchitis and Emphysema

COPD is an umbrella term. Historically clinicians spoke of two "types," and although most patients have features of both, the distinction still teaches the pathology well.

Chronic bronchitis is a clinical diagnosis: a chronic productive cough for at least three months in each of two consecutive years, once other causes are excluded. The pathology sits in the airways. Cigarette smoke irritates the bronchial lining, driving mucous gland hypertrophy and goblet cell hyperplasia, so the airways produce excess mucus. Chronic inflammation thickens the airway walls and impairs the cilia that should sweep mucus upward. The result is narrowed, clogged, inflamed airways — a cough that never quite clears and a breeding ground for infection.

Emphysema is an anatomical diagnosis: permanent enlargement of the airspaces distal to the terminal bronchioles due to destruction of alveolar walls, without obvious fibrosis. Here the damage is to the lung parenchyma itself. Two things go wrong at once. First, the walls between alveoli are digested away, so many small air sacs merge into fewer large ones — collapsing the enormous surface area needed for gas exchange. Second, the elastic fibres that give the lung its recoil are destroyed. Normally that recoil helps hold the small airways open and drives air out on exhalation; without it, airways collapse during expiration and air is trapped.

The classic (and oversimplified) clinical caricatures are worth knowing for exams. The "pink puffer" is the emphysema-predominant patient: thin, markedly breathless, using pursed-lip breathing to keep airways splinted open, maintaining near-normal blood gases at the cost of great effort. The "blue bloater" is the chronic-bronchitis-predominant patient: cyanosed, oedematous from cor pulmonale, with hypoxaemia and hypercapnia and a less dramatic sense of breathlessness. Real patients rarely fit neatly into one box.

The Alpha-1 Exception

Not all emphysema is from smoking. Alpha-1 antitrypsin (AAT) deficiency is an inherited disorder in which the liver produces too little of the protein that protects lung tissue from neutrophil elastase. Without it, the elastase released during inflammation digests the lung unopposed, causing early-onset emphysema — typically basal (lower-lobe) rather than the apical distribution of smoking-related disease — often in a patient under 45, sometimes with liver disease too. Any young or non-smoking patient with emphysema should be tested. This is the classic illustration of the protease-antiprotease imbalance that underlies emphysema in general.

Why the Air Gets Trapped: The Physiology of Airflow Limitation

The single unifying abnormality in COPD is expiratory airflow limitation. On spirometry this appears as a reduced FEV1 (the volume forced out in the first second) relative to the FVC (the total forced volume), giving an FEV1/FVC ratio below 0.70 that does not correct after a bronchodilator — the "not fully reversible" hallmark that separates COPD from asthma.

Follow the mechanics. Loss of elastic recoil and airway inflammation mean the small airways collapse early during exhalation. Air that should leave the lung is trapped behind these closed airways — this is hyperinflation. As the patient breathes faster (during exercise, for instance), there is not enough time to fully exhale before the next breath begins, so trapped volume accumulates breath by breath: dynamic hyperinflation. The chest becomes barrel-shaped, and the diaphragm is pushed down flat. A flat diaphragm is a mechanically inefficient diaphragm — it can no longer generate a good pressure drop — which is a major reason patients feel so breathless on exertion. This also explains why pursed-lip breathing helps: it creates back-pressure that keeps airways open longer, allowing more complete emptying.

As disease advances, ventilation-perfusion mismatch worsens gas exchange, producing hypoxaemia and, eventually, carbon dioxide retention. Chronic hypoxaemia constricts pulmonary arterioles, raising pulmonary artery pressure and straining the right heart — the pathway to cor pulmonale and peripheral oedema.

Confirming the Diagnosis and Staging Severity

Suspect COPD in anyone over 35 to 40 with a relevant exposure (smoking, occupational dusts, biomass fuel smoke) and any of: exertional breathlessness, chronic cough, regular sputum, or frequent winter "chest infections." But you must confirm it — clinical impression alone over- and under-diagnoses badly.

Spirometry is mandatory. A post-bronchodilator FEV1/FVC below 0.70 confirms persistent airflow limitation. The severity of the limitation is then graded by FEV1 as a percentage of predicted (GOLD grades):

GOLD grade	Severity	FEV1 (% predicted)
GOLD 1	Mild	80 or above
GOLD 2	Moderate	50 to 79
GOLD 3	Severe	30 to 49
GOLD 4	Very severe	less than 30

Modern GOLD guidance stresses that FEV1 alone does not capture how a patient does. The ABE assessment combines symptom burden — measured with tools such as the mMRC breathlessness scale or the CAT questionnaire — with exacerbation history. Group A is low symptoms and low exacerbation risk; Group B is high symptoms, low risk; Group E is anyone with frequent or severe exacerbations (two or more moderate exacerbations, or one leading to hospital admission, in a year). This drives initial inhaler choice.

Supporting tests include chest X-ray (hyperinflated flat-diaphragm lungs; also excludes other causes), full blood count (secondary polycythaemia from chronic hypoxia, and eosinophil count to guide steroid use), and AAT level in appropriate patients. Reversibility testing helps distinguish COPD from asthma, though the two can coexist.

Managing COPD: Changing the Trajectory

Worked example. A 64-year-old with a 45-pack-year history reports breathlessness walking up a slight hill (mMRC 2) and two courses of antibiotics for chest infections this year, one requiring admission. Post-bronchodilator FEV1 is 42% predicted (GOLD 3), FEV1/FVC 0.58. Blood eosinophils are 0.35. This is GOLD 3, Group E. His plan: unequivocal smoking-cessation support with pharmacotherapy; influenza, pneumococcal, and COVID vaccination; a LABA/LAMA combination inhaler — with ICS added given his exacerbation frequency and raised eosinophils; referral to pulmonary rehabilitation; and a written action plan with rescue medication for future exacerbations.

The management ladder, in priority order:

1. Smoking cessation — the only intervention that slows the decline in lung function and reduces mortality. Combine behavioural support with nicotine replacement, varenicline, or bupropion. This matters more than any inhaler.
2. Vaccination — annual influenza, pneumococcal, and COVID vaccines reduce exacerbations and deaths.
3. Pulmonary rehabilitation — a structured exercise and education programme that reliably improves breathlessness, exercise capacity, and quality of life; one of the highest-value treatments available and badly under-used.
4. Inhaled bronchodilators — long-acting muscarinic antagonists (LAMAs, e.g. tiotropium) and long-acting beta-2 agonists (LABAs) are the backbone. LABA/LAMA combinations outperform either alone for symptoms and exacerbations.
5. Inhaled corticosteroids (ICS) — added (as LABA/LAMA/ICS "triple therapy") for patients with frequent exacerbations, especially with higher blood eosinophils or an asthma overlap. ICS carry a pneumonia risk, so they are targeted, not universal.
6. Long-term oxygen therapy (LTOT) — for chronic resting hypoxaemia (PaO2 at or below 7.3 kPa, or 7.3–8.0 kPa with cor pulmonale/polycythaemia). Used at least 15 hours a day, it is one of only two interventions (with smoking cessation) proven to prolong life in COPD. It must never be given to a still-smoking patient because of fire risk.
7. Other measures — roflumilast (a PDE-4 inhibitor) and azithromycin for selected frequent exacerbators; pulmonary rehabilitation reinforcement; lung-volume-reduction surgery or endobronchial valves for carefully chosen severe emphysema; and, at the end, honest conversations about palliative care for refractory breathlessness.

Acute Exacerbations

An exacerbation is an acute worsening of respiratory symptoms — more breathlessness, more sputum, or more purulent sputum — beyond normal day-to-day variation, usually triggered by viral or bacterial infection or pollution. These are pivotal events: each one can drop lung function a notch that never fully recovers, and hospital admissions carry real mortality.

Treatment follows a clear pattern: increase short-acting bronchodilators (salbutamol and ipratropium via nebuliser or spacer); a short course of oral prednisolone (typically 30 mg for five days); antibiotics if sputum is purulent or there are clinical signs of infection; and controlled oxygen targeting an SpO2 of 88–92%, not the 94–98% used in most patients. This target is critical: some COPD patients rely on hypoxic drive and can retain CO2 dangerously if given high-flow oxygen. Patients with respiratory acidosis (a rising CO2 and falling pH) who do not respond may need non-invasive ventilation (BiPAP), which has transformed survival in this setting.

Real-World Applications

In everyday clinical practice, COPD is a bread-and-butter diagnosis in general practice, emergency departments, and medical wards. Recognising an exacerbation early and starting the right treatment prevents admissions. Knowing the 88–92% oxygen target can literally prevent an iatrogenic death from CO2 narcosis. On a population level, the disease is a public-health argument for tobacco control, cleaner cooking fuels, and occupational dust regulation. For patients and families, understanding that stopping smoking still helps even after diagnosis — because it changes the slope of decline, not the damage already done — is one of the most motivating messages a clinician can deliver. Pulmonary rehabilitation, an "everyday" intervention with no pharmacology at all, often does more for a patient's daily life than another inhaler.

Common Mistakes

• Diagnosing COPD without spirometry. Breathlessness and a smoking history are not enough — heart failure, asthma, and other conditions mimic COPD. The correction: always confirm with post-bronchodilator spirometry showing FEV1/FVC below 0.70 before labelling a patient for life.
• Giving high-flow oxygen in an exacerbation. Aiming for normal saturations (94–98%) in a CO2-retaining COPD patient can suppress ventilation and precipitate acidosis and coma. The correction: target 88–92% with controlled oxygen and check blood gases.
• Treating COPD like asthma with routine ICS for everyone. ICS are not first-line in COPD and increase pneumonia risk; they belong to a targeted group (frequent exacerbators, high eosinophils, asthma overlap). The correction: base ICS on exacerbation history and eosinophils, and lead with LABA/LAMA.
• Prioritising inhalers over smoking cessation. No inhaler slows disease progression; stopping smoking does. The correction: make cessation the central, repeated intervention at every visit.

Comparison and Connections

The most important distinction to master is COPD versus asthma, because their treatments diverge.

Feature	COPD	Asthma
Typical onset	Usually after 40, smoking history	Often childhood/young adult
Airflow limitation	Persistent, not fully reversible	Variable, largely reversible
Course	Progressive	Episodic with good baseline
Reversibility on spirometry	Minimal	Often significant
Cornerstone therapy	Smoking cessation, LABA/LAMA	Inhaled corticosteroids
Eosinophilic inflammation	Sometimes	Usually

Some patients have features of both — asthma-COPD overlap — and need ICS earlier. COPD also connects to cardiovascular disease (shared smoking risk and systemic inflammation), to right heart failure via cor pulmonale, and to lung cancer, which shares the same principal cause. Bronchiectasis and heart failure are its main breathless-cough mimics.

Practice Questions

Recall

Q: What post-bronchodilator spirometry finding is required to diagnose COPD? A: An FEV1/FVC ratio below 0.70, confirming persistent airflow limitation that is not fully reversible.

Understanding

Q: Explain why a COPD patient develops a barrel chest and a flat diaphragm. A: Loss of elastic recoil and early airway collapse trap air in the lungs (hyperinflation). The chronically overinflated lungs expand the rib cage into a barrel shape and push the diaphragm downward and flat, which reduces its mechanical efficiency and worsens breathlessness.

Application

Q: A COPD patient arrives in the ED with an exacerbation and an SpO2 of 84%. The nurse asks what oxygen target to set. What do you say and why? A: Target 88–92% using controlled oxygen (e.g. a Venturi mask). Some COPD patients retain CO2, and high-flow oxygen aiming for normal saturations can suppress ventilation and cause dangerous CO2 retention and acidosis. Check an arterial blood gas.

Analysis

Q: Two interventions are proven to reduce mortality in COPD. Identify them and explain why they, rather than bronchodilators, have this effect. A: Smoking cessation and long-term oxygen therapy. Smoking cessation alters the underlying disease trajectory by flattening the accelerated FEV1 decline (Fletcher-Peto). LTOT corrects chronic hypoxaemia, reducing pulmonary hypertension and cor pulmonale. Bronchodilators improve symptoms and reduce exacerbations but do not clearly prolong survival because they do not address the driving pathology.

FAQ

Is COPD reversible? Can lungs heal after quitting smoking? The structural damage — destroyed alveoli, scarred airways — does not reverse. But quitting slows further loss of lung function and reduces exacerbations, so the future trajectory improves substantially. It is always worth stopping, at any stage.

What is the difference between COPD and emphysema? Emphysema is one component of COPD — the destruction of alveolar walls. COPD is the broader diagnosis of persistent airflow limitation, which usually combines emphysema with chronic bronchitis (airway disease).

Can non-smokers get COPD? Yes. Causes include alpha-1 antitrypsin deficiency, long-term exposure to biomass cooking smoke (a huge global cause), occupational dusts and fumes, severe air pollution, and poorly controlled childhood asthma.

Why is my inhaler not "curing" the breathlessness? Inhalers open the airways and reduce flare-ups, improving symptoms, but they cannot rebuild lost lung tissue. Pulmonary rehabilitation and exercise often improve daily function more than adjusting inhalers.

How is COPD different from asthma if both cause wheeze? Asthma airflow limitation is variable and largely reversible, often starting young; COPD limitation is persistent, progressive, and tied to long exposure such as smoking. Their first-line treatments differ, which is why getting the diagnosis right matters.

Quick Revision

• COPD = persistent, not-fully-reversible airflow limitation; mainly caused by smoking.
• Two components: chronic bronchitis (cough, sputum, airway disease) and emphysema (alveolar destruction, lost recoil, gas trapping).
• Diagnose with post-bronchodilator FEV1/FVC below 0.70; grade severity by FEV1% predicted (GOLD 1–4).
• Assess symptoms + exacerbations (ABE groups) to guide inhaler choice.
• Only smoking cessation and long-term oxygen prolong survival.
• Backbone therapy: LABA + LAMA; add ICS for frequent exacerbators / high eosinophils.
• Pulmonary rehabilitation and vaccination are high-value and under-used.
• Exacerbation: bronchodilators + prednisolone + antibiotics if purulent; oxygen target 88–92%; NIV for respiratory acidosis.
• Suspect alpha-1 antitrypsin deficiency in young or non-smoking emphysema.

Related Topics

Prerequisites

• Pulmonology overview
• Respiratory physiology and gas exchange (see ../../2._Physiology/index.md)

Related Topics

• Asthma (sibling topic in this branch)
• Respiratory failure and non-invasive ventilation
• Cor pulmonale and pulmonary hypertension (see ../../25._Cardiology/index.md)

Next Topics

• Acute exacerbation management and NIV
• Long-term oxygen therapy assessment
• Lung cancer screening in smokers (see ../../32._Oncology/index.md)